流感 H3 和 H1 病毒对 HA 茎抗体的耐药性存在不同的遗传屏障。
Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses.
机构信息
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
出版信息
Science. 2020 Jun 19;368(6497):1335-1340. doi: 10.1126/science.aaz5143.
Abstract
The discovery and characterization of broadly neutralizing human antibodies (bnAbs) to the highly conserved stem region of influenza hemagglutinin (HA) have contributed to considerations of a universal influenza vaccine. However, the potential for resistance to stem bnAbs also needs to be more thoroughly evaluated. Using deep mutational scanning, with a focus on epitope residues, we found that the genetic barrier to resistance to stem bnAbs is low for the H3 subtype but substantially higher for the H1 subtype owing to structural differences in the HA stem. Several strong resistance mutations in H3 can be observed in naturally circulating strains and do not reduce in vitro viral fitness and in vivo pathogenicity. This study highlights a potential challenge for development of a truly universal influenza vaccine.
摘要
广谱中和人类抗体（bnAbs）对流感血凝素（HA）高度保守茎区的发现和鉴定，推动了对通用流感疫苗的考虑。然而，对茎部 bnAbs 产生耐药性的可能性也需要更彻底的评估。通过深度突变扫描，重点是表位残基，我们发现 H3 亚型对茎部 bnAbs 的耐药性遗传障碍较低，而由于 HA 茎部结构的差异，H1 亚型的耐药性遗传障碍则大大增加。在自然循环株中可以观察到几个 H3 中的强耐药突变，并且不会降低体外病毒适应性和体内致病性。本研究突出了开发真正通用流感疫苗的一个潜在挑战。
相似文献
1
Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses.流感 H3 和 H1 病毒对 HA 茎抗体的耐药性存在不同的遗传屏障。
Science. 2020 Jun 19;368(6497):1335-1340. doi: 10.1126/science.aaz5143.
2
Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.新型 H3 特异性广谱中和单克隆抗体的鉴定 该抗体靶向血凝素球状头部，来源于一位具有广泛血清学反应性的流感病毒免疫供者
J Virol. 2020 Feb 28;94(6). doi: 10.1128/JVI.01035-19.
3
Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.二价 H1 和 H3 COBRA 重组血凝素疫苗可诱导针对 2009 年至 2019 年 H1N1 和 H3N2 流感病毒的血清保护性抗体。
J Virol. 2022 Apr 13;96(7):e0165221. doi: 10.1128/jvi.01652-21. Epub 2022 Mar 15.
4
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.一种针对流感病毒 H3 血凝素球形头部上新的保守表位的广谱中和人源单克隆抗体。
J Virol. 2014 Jun;88(12):6743-50. doi: 10.1128/JVI.03562-13. Epub 2014 Apr 2.
5
Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions.重组流感血凝素外域融合蛋白的保护效力。
Viruses. 2021 Aug 27;13(9):1710. doi: 10.3390/v13091710.
6
Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses.用同时表达猪 H1N1 和 H3N2 流感病毒 HA1 基因的重组猪痘病毒对豚鼠进行免疫保护。
Arch Virol. 2013 Mar;158(3):629-37. doi: 10.1007/s00705-012-1539-9. Epub 2012 Nov 8.
7
Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.在对历史 H3N2 流感病毒无预存免疫的雪貂中引发针对未来 20 年 H3N2 共循环流感病毒变异株的保护性抗体。
J Virol. 2019 Jan 17;93(3). doi: 10.1128/JVI.00946-18. Print 2019 Feb 1.
8
Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.通过去除流感病毒血凝素蛋白的N-连接糖基化位点来揭示茎特异性中和表位用于疫苗设计
J Virol. 2016 Sep 12;90(19):8496-508. doi: 10.1128/JVI.00880-16. Print 2016 Oct 1.
9
Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.对展示来自H1、H3和B亚型流感HA2的三价嵌合诺如病毒P颗粒免疫原的免疫原性和保护作用的评估。
Emerg Microbes Infect. 2016 May 25;5(5):e51. doi: 10.1038/emi.2016.51.
10
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.稳定的三聚体流感血凝素茎作为一种广泛保护性的免疫原。
Science. 2015 Sep 18;349(6254):1301-6. doi: 10.1126/science.aac7263. Epub 2015 Aug 24.
引用本文的文献
1
Functional, Immunogenetic, and Structural Convergence in Influenza Immunity between Humans and Macaques.人类与猕猴流感免疫中的功能、免疫遗传和结构趋同
bioRxiv. 2025 Feb 27:2025.02.21.639368. doi: 10.1101/2025.02.21.639368.
2
Pleiotropic mutational effects on function and stability constrain the antigenic evolution of influenza hemagglutinin.对功能和稳定性的多效性突变效应限制了流感血凝素的抗原进化。
bioRxiv. 2025 May 24:2025.05.24.655919. doi: 10.1101/2025.05.24.655919.
3
Balancing stability and function: impact of the surface charge of SARS-CoV-2 Omicron spike protein.平衡稳定性与功能：新型冠状病毒奥密克戎变异株刺突蛋白表面电荷的影响
Npj Viruses. 2025 Apr 1;3(1):23. doi: 10.1038/s44298-025-00104-1.
4
Public antibodies: convergent signatures in human humoral immunity against pathogens.公共抗体：人类针对病原体的体液免疫中的趋同特征
mBio. 2025 May 14;16(5):e0224724. doi: 10.1128/mbio.02247-24. Epub 2025 Apr 16.
5
Antigenic drift expands influenza viral escape pathways from recalled humoral immunity.抗原漂移扩展了流感病毒逃避回忆性体液免疫的途径。
Immunity. 2025 Mar 11;58(3):716-727.e6. doi: 10.1016/j.immuni.2025.02.006. Epub 2025 Feb 28.
6
Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of V3 and V3 genes.源自不同疫苗策略的结构趋同抗体利用一部分V3和V3基因靶向流感病毒HA锚定表位。
Nat Commun. 2025 Feb 2;16(1):1268. doi: 10.1038/s41467-025-56496-4.
7
Administration of antigenically distinct influenza viral particle combinations as an influenza vaccine strategy.给予抗原性不同的流感病毒颗粒组合作为一种流感疫苗策略。
PLoS Pathog. 2025 Jan 22;21(1):e1012878. doi: 10.1371/journal.ppat.1012878. eCollection 2025 Jan.
8
Influenza A Virus H7 nanobody recognizes a conserved immunodominant epitope on hemagglutinin head and confers heterosubtypic protection.甲型流感病毒H7纳米抗体识别血凝素头部保守的免疫显性表位并提供异源亚型保护。
Nat Commun. 2025 Jan 9;16(1):432. doi: 10.1038/s41467-024-55193-y.
9
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen.使用马H3N8血凝素作为一种具有广泛保护作用的流感疫苗免疫原。
NPJ Vaccines. 2024 Dec 19;9(1):247. doi: 10.1038/s41541-024-01037-1.
10
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.评估2组流感血凝素稳定化茎部纳米颗粒疫苗的1期剂量递增试验。
NPJ Vaccines. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0.
本文引用的文献
1
A small-molecule fusion inhibitor of influenza virus is orally active in mice.小分子流感病毒融合抑制剂在小鼠体内具有口服活性。
Science. 2019 Mar 8;363(6431). doi: 10.1126/science.aar6221.
2
Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.纳米颗粒组 2 流感病毒血凝素茎抗原的设计可激活广谱中和抗体谱系中未突变的祖先 B 细胞受体。
mBio. 2019 Feb 26;10(1):e02810-18. doi: 10.1128/mBio.02810-18.
3
Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.流感病毒血凝素的免疫优势和抗原变异：对通用疫苗免疫原设计的启示。
J Infect Dis. 2019 Apr 8;219(Suppl_1):S38-S45. doi: 10.1093/infdis/jiy696.
4
Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants.血凝素的深度突变扫描有助于预测人类 H3N2 流感变异株的进化命运。
Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8276-E8285. doi: 10.1073/pnas.1806133115. Epub 2018 Aug 13.
5
The influenza virus hemagglutinin head evolves faster than the stalk domain.流感病毒血凝素头部比茎部进化得更快。
Sci Rep. 2018 Jul 11;8(1):10432. doi: 10.1038/s41598-018-28706-1.
6
How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin.单突变如何影响 H1 流感血凝素对广谱和窄谱抗体的病毒逃逸。
Nat Commun. 2018 Apr 11;9(1):1386. doi: 10.1038/s41467-018-03665-3.
7
Structural insights into the design of novel anti-influenza therapies.新型抗流感疗法设计的结构见解。
Nat Struct Mol Biol. 2018 Feb;25(2):115-121. doi: 10.1038/s41594-018-0025-9. Epub 2018 Feb 2.
8
Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain.H1 流感病毒血凝素茎结构域的自然定向抗原漂移。
Sci Rep. 2017 Nov 6;7(1):14614. doi: 10.1038/s41598-017-14931-7.
9
A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine.季节性流感H3N2疫苗有效性低的结构学解释。
PLoS Pathog. 2017 Oct 23;13(10):e1006682. doi: 10.1371/journal.ppat.1006682. eCollection 2017 Oct.
10
Potent peptidic fusion inhibitors of influenza virus.强效流感病毒肽类融合抑制剂。
Science. 2017 Oct 27;358(6362):496-502. doi: 10.1126/science.aan0516. Epub 2017 Sep 28.
Zotero 插件